Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
Crossref DOI link: https://doi.org/10.1007/s12185-016-2130-z
Published Online: 2016-11-10
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Komatsu, Norio
Kirito, Keita
Shimoda, Kazuya
Ishikawa, Takayuki
Ohishi, Kohshi
Ohyashiki, Kazuma
Takahashi, Naoto
Okada, Hikaru
Amagasaki, Taro
Yonezu, Toshio
Akashi, Koichi
Funding for this research was provided by:
Novartis Pharma K.K.
License valid from 2016-11-10